Loading...
•
Mar 31, 2024
Verrica Q1 2024 Earnings Report
Reported YCANTH® revenue of $3.2M and collaboration revenues of $0.6M.
Key Takeaways
Verrica Pharmaceuticals reported first quarter 2024 financial results, highlighting YCANTH® revenue of $3.2 million and collaboration revenue of $0.6 million. The company also received a permanent J-Code from CMS and secured new chemical entity status from the FDA for YCANTH.
YCANTH revenue reached $3.2 million in Q1 2024.
Over 228 million lives are now covered under commercial insurance, managed Medicaid, Tricare, and Federal Employee plans.
Preliminary Phase 2 results for VP-315 in treating basal cell carcinoma are expected in Q2 2024.
A permanent J-Code for YCANTH was secured from CMS, effective April 1, 2024.
Forward Guidance
Verrica believes that its existing cash and cash equivalents as of March 31, 2024 will be sufficient to support planned operations into the first quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...